Literature DB >> 32016022

Proteomic analysis of PAX8 alterations provides new insights into its role as a master regulator of migration in high-grade serous ovarian cancer.

Tania Gamberi1.   

Abstract

Entities:  

Year:  2019        PMID： 32016022      PMCID： PMC6976517          DOI： 10.21037/atm.2019.10.100

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  The transcription factor FOXM1 is a cellular target of the natural product thiostrepton.

Authors:  Nagaratna S Hegde; Deborah A Sanders; Raphaël Rodriguez; Shankar Balasubramanian
Journal:  Nat Chem       Date:  2011-08-21       Impact factor: 24.427

2.  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.

Authors:  Hiu Wing Cheung; Glenn S Cowley; Barbara A Weir; Jesse S Boehm; Scott Rusin; Justine A Scott; Alexandra East; Levi D Ali; Patrick H Lizotte; Terence C Wong; Guozhi Jiang; Jessica Hsiao; Craig H Mermel; Gad Getz; Jordi Barretina; Shuba Gopal; Pablo Tamayo; Joshua Gould; Aviad Tsherniak; Nicolas Stransky; Biao Luo; Yin Ren; Ronny Drapkin; Sangeeta N Bhatia; Jill P Mesirov; Levi A Garraway; Matthew Meyerson; Eric S Lander; David E Root; William C Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

3.  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Authors:  Kevin M Elias; Megan M Emori; Thomas Westerling; Henry Long; Anna Budina-Kolomets; Fugen Li; Emily MacDuffie; Michelle R Davis; Alexander Holman; Brian Lawney; Matthew L Freedman; John Quackenbush; Myles Brown; Ronny Drapkin
Journal:  JCI Insight       Date:  2016-08-18

4.  Histopathologic features of genetically determined ovarian cancer.

Authors:  P A Shaw; J R McLaughlin; R P Zweemer; S A Narod; H Risch; R H M Verheijen; A Ryan; F H Menko; P Kenemans; I J Jacobs
Journal:  Int J Gynecol Pathol       Date:  2002-10       Impact factor: 2.762

5.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

6.  A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells.

Authors:  Tina Di Palma; Valeria Lucci; Tiziana de Cristofaro; Maria Grazia Filippone; Mariastella Zannini
Journal:  BMC Cancer       Date:  2014-04-26       Impact factor: 4.430

Review 7.  Cell Origins of High-Grade Serous Ovarian Cancer.

Authors:  Jaeyeon Kim; Eun Young Park; Olga Kim; Jeanne M Schilder; Donna M Coffey; Chi-Heum Cho; Robert C Bast
Journal:  Cancers (Basel)       Date:  2018-11-12       Impact factor: 6.639

8.  Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.

Authors:  Laura R Hardy; Melissa R Pergande; Karina Esparza; Kimberly N Heath; Hayat Önyüksel; Stephanie M Cologna; Joanna E Burdette
Journal:  Oncogene       Date:  2019-07-11       Impact factor: 9.867

9.  PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas.

Authors:  Li Xiang; Beihua Kong
Journal:  Oncol Lett       Date:  2013-01-10       Impact factor: 2.967

10.  Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.

Authors:  Laura H Rodgers; Eoghainín Ó hAinmhire; Alexandria N Young; Joanna E Burdette
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.